A solution for tissue tethering earns Aliform the top spot at MedTech World North America 2026 Startup Pitch Competition
Article first published on MedTech World website on May 14, 2026.
To demonstrate the product’s commercial potential, Suturin outlined the economics behind it. Clinics charge between $3,000 and $6,000 per procedure, while the single-use Celluleaf device costs approximately $1,000. He estimated that the U.S. market alone includes more than 15,000 plastic surgery clinics, with surgeons performing anywhere between 50 and 200 procedures annually.
Suturin shared that Celluleaf is now available in the United States and Canada after five years of development and is already being used by more than 10 surgeons across 15 clinical applications, including fibrous adhesions, cellulite, and lipedema. He also revealed that the company completed its first 20 sales last month.
Rather than immediately scaling aggressively, Suturin emphasized that Aliform’s current priority is validating repeat sales and refining its commercialization strategy.
“The next goal, as framed to us by our strategics, is ten to twenty clinics with repeat sales. We do that, we prove commercial viability.”
The judges used the Q&A session to explore the broader implications of the technology. When asked whether the device causes additional injury or scarring, Suturin clarified that the procedure instead relieves existing scar tension and restores a more natural force distribution beneath the skin. He compared the process to “breaking the weeds of the soil.”
The discussion also explored future applications beyond aesthetics, including breast reconstruction after cancer treatment, radiation fibrosis, traumatic scar correction, and smaller cosmetic procedures performed in med spas.
When questioned about reimbursement pathways, Suturin explained that reconstructive applications may qualify for reimbursement codes, but Aliform is initially focusing on the private-pay aesthetics market to build traction while preparing for larger clinical studies in the future.
The company currently operates from the Texas Medical Center in Houston, with a production subsidiary in the Netherlands. Suturin noted that Aliform’s 10-person team has largely been composed of scientists and PhDs during the product development phase, with the company now beginning to expand its commercial expertise as it enters the U.S. market.
As the pitch neared its conclusion, one of the judges raised the potential impact of GLP-1 weight-loss drugs on the market opportunity. Suturin agreed that significant weight loss often leads to contour irregularities and additional aesthetic procedures, creating further demand for technologies that address tissue tethering and skin irregularities.
The presentation resonated strongly with both judges and attendees, ultimately earning Aliform the top prize in the MedTech World Startup Pitch Competition at MedTech World North America 2026.
